FDG-PET imaging in the management of non-small-cell lung cancer

被引：10
作者：
Salminen, E
Mac Manus, M
机构：
[1] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
来源：
ANNALS OF ONCOLOGY | 2002年 / 13卷 / 03期
关键词：
FDG-PET; non-small-cell lung cancer; outcome; staging; treatment;
D O I：
10.1093/annonc/mdf106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancer is currently the leading cause of cancer-related death in both men and women in most Western countries. Tumour stage is the strongest prognostic factor and the most important parameter guiding treatment decision making. Metabolic positron emission tomography imaging with fluorodeoxyglucose (FDG-PET) has consistently proved superior to conventional imaging for staging of non-small-cell lung cancer and provides information of greater prognostic significance than can be obtained using conventional approaches. FDG-PET has been approved in the USA. Germany and the UK as a basic and invaluable tool in the management of lung cancer.
引用
收藏
页码：357 / 360
页数：4
相关论文
共 37 条
[31]  
Tesar Ruth, 1998, Clin Positron Imaging, V1, P51, DOI 10.1016/S1095-0397(97)00007-1
[32]   Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer:: An analysis of 125 cases [J].
Vansteenkiste, JF ;
Stroobants, SG ;
Dupont, PJ ;
De Leyn, PR ;
Verbeken, EK ;
Deneffe, GJ ;
Mortelmans, LA ;
Demedts, MG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3201-3206
[33]   The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer [J].
Vanuytsel, LJ ;
Vansteenkiste, JF ;
Stroobants, SG ;
De Leyn, PR ;
De Wever, W ;
Verbeken, EK ;
Gatti, GG ;
Huyskens, DP ;
Kutcher, GJ .
RADIOTHERAPY AND ONCOLOGY, 2000, 55 (03) :317-324
[34]  
Vesselle H, 2000, CLIN CANCER RES, V6, P3837
[35]   Detection of extrathoracic metastases by positron emission tomography in lung cancer [J].
Weder, W ;
Schmid, RA ;
Bruchhaus, H ;
Hillinger, S ;
von Schulthess, GK ;
Steinert, HC .
ANNALS OF THORACIC SURGERY, 1998, 66 (03) :886-892
[36]   Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer [J].
Weng, E ;
Tran, L ;
Rege, S ;
Safa, A ;
Sadeghi, A ;
Juillard, G ;
Mark, R ;
Santiago, S ;
Brown, C ;
Mandelkern, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01) :47-52
[37]   Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography:: Review and 1999 EORTC recommendations [J].
Young, H ;
Baum, R ;
Cremerius, U ;
Herholz, K ;
Hoekstra, O ;
Lammertsma, AA ;
Pruim, J ;
Price, P .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (13) :1773-1782
1234